Starling Oncology
Starling Oncology's revenue rose 27.8% to $503 million in fiscal 2025. Its operating margin was −7.2%, up from −15.3% a year earlier. Free cash flow was −$28 million. The diluted share count rose 23.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Starling Oncology does
The company, formerly named The Oncology Institute and listed on this site as Starling Oncology, runs cancer care clinics. It began in 2007 as a group of community oncology practices in southern California and now treats patients in 17 markets across five states. It offers medical oncology (infusion therapy), radiation therapy, hematology, specialty infusion and an oral pharmacy, and enrolls patients in clinical trials where appropriate.
It makes money two ways. In its fee-for-service business it bills insurers for physician services, infusions, radiation and drugs. In its value-based business it contracts with health plans and other risk-bearing organizations that pay it a fixed amount per member, or share gains and losses, in return for managing patients' outpatient cancer care. It then carries the risk that care costs more than it is paid.
It has 65 clinics owned by affiliated physicians, 81 independently owned clinics under its managed services organization, and a contracted network of independent providers. It managed care for about 2.0 million patients under value-based agreements at the end of 2025.
Its biggest risks, as it describes them
- It must build or buy more clinics to serve its contracts, and rapid growth strains its organization.
- It has a history of net losses and may not reach profitability.
- Under value-based contracts it bears the risk that patients' care costs more than it is paid.
- A large share of its revenue comes from a limited number of insurers and payors.
- Cuts in government reimbursement or rule changes could hurt it.
Income statement
Starling Oncology lost money in fiscal 2025: a net loss of $61 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 115 | 74 | 83 | 50 | 34 |
| Debt incl. finance leases | 0 | 81 | 87 | 93 | 78 |
| Net debt (negative means net cash) | −115 | 7 | 4 | 44 | 44 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.7x | 1.5x | — | — |
| Interest coverage | −143.3x | −365.9x | −11.4x | −8.0x | −3.2x |
| Current ratio | 5.2x | 4.4x | 4.1x | 2.1x | 1.6x |
| Quick ratio | 5.0x | 4.1x | 3.7x | 2.0x | 1.4x |
Cash flow
Projections
Project Starling Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Starling Oncology reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 3 of 8 | 3 of 8 |
| Rule of 40 | 15.8% | 13.6% | 22.3% |
| Altman Z'' | −0.95 | −4.01 | −5.27 |
| Accruals ratio | −19.9% | −20.0% | −21.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 2 of 8 | 3 of 8 | 3 of 8 |
Compare
Put Starling Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Starling Oncology | FY25 | 27.8% | −7.2% | −5.5% | −75.7% | — | 3 | |
| Veracyte | FY25 | 16.0% | 11.2% | 24.5% | 6.1% | −4.6x | 6 | Compare |
| GeneDx | FY25 | 40.0% | −3.1% | 3.3% | −5.3% | — | 6 | Compare |
| CareDx | FY25 | 13.8% | −8.1% | — | −20.0% | — | 4 | Compare |
| NeoGenomics Laboratories | FY25 | 10.1% | −15.9% | −3.0% | −8.8% | — | 5 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 188 | 203 | 252 | 324 | 393 | 503 |
| Revenue growth | — | 8.3% | 24.4% | 28.4% | 21.3% | 27.8% |
| Gross profit | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — |
| Operating income | −8 | −46 | −82 | −77 | −60 | −36 |
| Net income | −14 | −11 | 0 | −83 | −65 | −61 |
| Diluted EPS (US$) | −0.24 | −0.16 | −0.21 | −0.92 | −0.71 | −0.54 |
| Diluted shares (millions) | 59 | 66 | 81 | 74 | 75 | 92 |
| Cash flow | ||||||
| Cash from operations | 0 | −33 | −62 | −36 | −26 | −25 |
| Capital expenditure | 1 | 3 | 6 | 5 | 4 | 3 |
| Free cash flow | −1 | −36 | −67 | −41 | −30 | −28 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 9 | 1 | 0 | 0 |
| Acquisitions | 0 | 9 | 9 | 4 | 0 | 0 |
| Stock-based compensation | 0 | 24 | 28 | 18 | 11 | 5 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 1 | 115 | 74 | 83 | 50 | 34 |
| Debt incl. finance leases | 12 | 0 | 81 | 87 | 93 | 78 |
| Total assets | 66 | 203 | 262 | 209 | 173 | 165 |
| Total liabilities | 38 | 99 | 138 | 152 | 169 | 180 |
| Shareholders' equity | 28 | 104 | 123 | 57 | 4 | −16 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −4.4% | −22.6% | −32.5% | −23.8% | −15.3% | −7.2% |
| Net margin | −7.6% | −5.4% | 0.1% | −25.6% | −16.4% | −12.1% |
| Free cash flow margin | −0.4% | −17.5% | −26.6% | −12.6% | −7.7% | −5.5% |
| Rule of 40 (growth + FCF margin) | — | −9.2% | −2.3% | 15.8% | 13.6% | 22.3% |
| Return on capital | — | −256.1% | −108.5% | −63.6% | −87.7% | −75.7% |
| Return on equity | — | −16.5% | 0.1% | −92.2% | −213.4% | — |
| Return on assets | — | −8.1% | 0.1% | −35.3% | −33.9% | −35.9% |
| Net debt to EBITDA | — | — | — | — | — | — |